Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
Sollip Kim, Hyun-Jung Kim, Hyeong-Sik Ahn, Se Won Oh, Kum Hyun Han, Tae-Hyun Um, Chong-Rae Cho, Sang Youb Han
Kidney Res Clin Pract. 2017;36(3):274-281.   Published online 2017 Sep 30     DOI: https://doi.org/10.23876/j.krcp.2017.36.3.274
Citations to this article as recorded by Crossref logo
In vitro and in vivo ameliorative effects of polyphenols from purple potato leaves on renal injury and associated inflammation induced by hyperuricemia
Rui Sun, Juan Kan, Huahao Cai, Jinhai Hong, Changhai Jin, Man Zhang
Journal of Food Biochemistry.2022;[Epub]     CrossRef
Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression
Seokwoo Park, Jung Pyo Lee, Dong Ki Kim, Yon Su Kim, Chun Soo Lim, Karin Jandeleit-Dahm
PLOS ONE.2022; 17(2): e0264627.     CrossRef
Systematically Exploring the Chemical Ingredients and Absorbed Constituents of Polygonum capitatum in Hyperuricemia Rat Plasma Using UHPLC-Q-Orbitrap HRMS
Huanyu Guan, Pengfei Li, Qian Wang, Fanli Zeng, Daoping Wang, Mei Zhou, Meng Zhou, Xun He, Shanggao Liao, Weidong Pan
Molecules.2022; 27(11): 3521.     CrossRef
Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
Tunlanut Sapankaew, Kunlawat Thadanipon, Narisa Ruenroengbun, Kamolpat Chaiyakittisopon, Atiporn Ingsathit, Pawin Numthavaj, Nathorn Chaiyakunapruk, Gareth McKay, John Attia, Ammarin Thakkinstian
BMC Nephrology.2022;[Epub]     CrossRef
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update
Arrigo F. G. Cicero, Federica Fogacci, Masanari Kuwabara, Claudio Borghi
Medicina.2021; 57(1): 58.     CrossRef
Contentious Issues in Gout Management: The Story so Far
Mohamed Talaat, Kyle Park, Naomi Schlesinger
Open Access Rheumatology: Research and Reviews.2021; Volume 13: 111.     CrossRef
Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials
Xiang Liu, Yuxuan Qiu, Duohui Li, Jiaxing Tan, Xiuping Liang, Wei Qin
Frontiers in Pharmacology.2021;[Epub]     CrossRef
Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients
Arrigo F.G. Cicero, Federica Fogacci, Raffaele Ivan Cincione, Giuliano Tocci, Claudio Borghi
Medical Principles and Practice.2021; 30(2): 122.     CrossRef
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini
Cardiovascular Diabetology.2020;[Epub]     CrossRef
Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement
Rahul Valsaraj, Awadhesh Kumar Singh, Kalyan Kumar Gangopadhyay, Biswajit Ghoshdastidar, Ghanshyam Goyal, Masood Batin, Dibyendu Mukherjee, Upal Sengupta, Sanjay Chatterjee, Nilanjan Sengupta
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(2): 93.     CrossRef
A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3
Marta Novella-Navarro, Jose Luis Cabrera-Alarcon, Cesar Diaz-Torne, Francisco Aramburu-Muñoz, Iustina Janta, Maria Carmen Ortega de la O, Alejandro Prada-Ojeda, Luis Sala-Icardo, Ana Urruticoechea-Arana, Paloma García de la Peña Lefebvre, Enrique Calvo-Ar
Rheumatology International.2020; 40(7): 1081.     CrossRef
A Lanosteryl Triterpene (RA-3) Exhibits Antihyperuricemic and Nephroprotective Effects in Rats
Nomadlozi Blessings Hlophe, Andrew Rowland Opoku, Foluso Oluwagbemiga Osunsanmi, Trayana Georgieva Djarova-Daniels, Oladipupo Adejumobi Lawal, Rebamang Anthony Mosa
Molecules.2020; 25(17): 4010.     CrossRef
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review
Anna M. Hu, Jamie N. Brown
Clinical Rheumatology.2020; 39(11): 3287.     CrossRef
Baseline characteristics of the autosomal‐dominant polycystic kidney disease sub‐cohort of the KoreaN cohort study for outcomes in patients with chronic kidney disease
Hyunsuk Kim, Junga Koh, Sue K Park, Kook H Oh, Yeong H Kim, Yaeni Kim, Curie Ahn, Yun K Oh
Nephrology.2019; 24(4): 422.     CrossRef
Effects of febuxostat on renal function in patients with chronic kidney disease
Tsu-Chen Lin, Lie Yee Hung, Ying-Chun Chen, Wei-Cheng Lo, Chun Hung Lin, Ka-Wai Tam, Mei-Yi Wu
Medicine.2019; 98(29): e16311.     CrossRef
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
Ting-Ting Chung, Kuang-Hui Yu, Chang-Fu Kuo, Shue-Fen Luo, Meng-Jiun Chiou, Wen-Ching Lan, Jung-Sheng Chen, Wen-Yi Tseng, Ao-Ho Hsieh, Lian-Chin Wang
Arthritis Research & Therapy.2019;[Epub]     CrossRef
Antioxidant, Anti-Melanogenic and Anti-Wrinkle Effects ofPhellinus vaninii
Kyung Hoan Im, Seung A Baek, Jaehyuk Choi, Tae Soo Lee
Mycobiology.2019; 47(4): 494.     CrossRef
Metabolomics analysis elucidates unique influences on purine / pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury
Takashi Tani, Ken Okamoto, Megumi Fujiwara, Akira Katayama, Shuichi Tsuruoka
Molecular Medicine.2019;[Epub]     CrossRef
Pharmacological urate-lowering approaches in chronic kidney disease
Xinrui Li, Jing Liu, Liang Ma, Ping Fu
European Journal of Medicinal Chemistry.2019; 166: 186.     CrossRef
Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
John A. Cuenca, Javier Balda, Ana Palacio, Larry Young, Michael H. Pillinger, Leonardo Tamariz
International Journal of Rheumatology.2019; 2019: 1.     CrossRef
Xanthine Oxidase Inhibition by Febuxostat in Macrophages Suppresses Angiotensin II-Induced Aortic Fibrosis
Masateru Kondo, Masaki Imanishi, Keijo Fukushima, Raiki Ikuto, Yoichi Murai, Yuya Horinouchi, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami, Kenshi Takechi, Masayuki Chuma, Yasumasa Ikeda, Hiromichi Fujino, Koichiro Tsuchiya, Keisuke Ishizawa
American Journal of Hypertension.2019; 32(3): 249.     CrossRef
Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
Amayelle Rey, Benjamin Batteux, Solène M. Laville, Justine Marienne, Kamel Masmoudi, Valérie Gras-Champel, Sophie Liabeuf
Arthritis Research & Therapy.2019;[Epub]     CrossRef
Effects of febuxostat on serum cytokines IL‑1, IL‑4, IL‑6, IL‑8, TNF‑α and COX‑2
Guohua Hao, Wei Duan, Jianping Sun, Jingyao Liu, Bo Peng
Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
Anti-fibrotic treatments: A review of clinical evidence
Marco Allinovi, Letizia De Chiara, Maria Lucia Angelotti, Francesca Becherucci, Paola Romagnani
Matrix Biology.2018; 68-69: 333.     CrossRef
The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
Dong-Ryeol Ryu
Kidney Research and Clinical Practice.2017; 36(3): 207.     CrossRef